leisure time -WSS

leisure time

author：focus 2025-09-27 23:54:09 - browse：27384

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Congressmen charge Covid hearing ‘could have been an email’

WSS

General Catalyst, Summa Health deal will turn on physician buy

ARCH Venture Partners is raising $3 billion for a life sciences fund

Quicker fix for pulse oximeters urged during FDA public meeting

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Merck drug for rare lung condition set for approval in U.S.

Eliminate the waiting period for sterilization covered by Medicaid

focus

leisure time

explore

Hepatitis C has a cure — but many Americans still lack access to it

Eliminate the waiting period for sterilization covered by Medicaid

The high cost of giving birth even with insurance

Scientists boost immune system in aging mice by making it youthful

Affirmative action in medical school literally saved lives

Vertigo drug brings hope for rare neuron disorder, Niemann

Walensky prepares to leave CDC — and Congress — behind

What we need to know about Arena Bioworks

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

leisure time

FDA drug safety: Singulair case shows systemic surveillance flaws

Novo Nordisk to expand supply of Wegovy for U.S. patients

The real point of Kenneth Smith’s execution by nitrogen gas

Woodcock on FDA’s accelerated approval and her next chapter

Congressmen charge Covid hearing ‘could have been an email’

Vertex non

focus

hotspot

focus

explore